×
Zoetis Total Assets 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis total assets for the quarter ending June 30, 2024 were
$14.165B
, a
3.03% increase
year-over-year.
Zoetis total assets for 2023 were
$14.286B
, a
4.28% decline
from 2022.
Zoetis total assets for 2022 were
$14.925B
, a
7.37% increase
from 2021.
Zoetis total assets for 2021 were
$13.9B
, a
2.14% increase
from 2020.
View More
Zoetis Total Assets 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zoetis total assets for 2023 were
$14.286B
, a
4.28% decline
from 2022.
Zoetis total assets for 2022 were
$14.925B
, a
7.37% increase
from 2021.
Zoetis total assets for 2021 were
$13.9B
, a
2.14% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Corcept Therapeutics (CORT)
$4.1B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B
Ardelyx (ARDX)
$1.4B